Regulation 30 Restructuring

LAURUS LABS LIMITED

General Information

BSE Scrip Code*	540222
NSE Symbol*	LAURUSLABS
MSEI Symbol*	NOTLISTED
ISIN*	INE947Q01028
Type of Announcement*	New
Type of Event	Acquisition (including agreement to acquire)
Whether Event/Information disclosed is an Outcome of Board Meeting?*	Yes
Date of Board Meeting	29-10-2026
End Time of Board Meeting	14:47:00
Date of occurrence of event
Time of occurrence of event
Date of initial announcement
Date of latest announcement
Date of Report	30-10-2026
Remarks (website dissemination)	Please note that the Turnover, PAT and Networth of the Target Company is mentioned in Canadian Dollar and the Cash Consideration / Cost of Acquisition is mentioned in USD in Crore in the 'Acquisition Sheet'. In order to avoid any confusion, please see below: Turnover of the target company: Canadian $ 1.65 million PAT of the target company: Canadian $ (0.23) million Networth of the target company: Canadian $ (0.26) million Consideration / Cost of acquisition: USD 3.75 million

Acquisition

Name of acquirer*

LAURUS LABS LIMITED

Relationship of acquirer with the listed entity*

Listed Entity (self)

Details of other relation with acquirer

Name of the target entity

Galenvs Sciences Inc.

Latest financial parameter of target entity

Turnover (Rs. in Crore)*

0.17

PAT (Rs. in Crore)*

(0.02)

Networth (Rs. in Crore)*

0.03

Other

Whether the acquisition would fall within Related Party Transaction(s)?*

Date of board meeting in which RPT approval taken

Date of audit committee meeting in which RPT approval taken

Whether the said RPT is material?*

Date of approval from shareholders

Whether the promoter/ promoter group/ group companies (including associate/ holding/ subsidiary)/ Director/ KMP/ SMP and its relatives have any interest in the entity being acquired?*

Nature of interest and details thereof

Whether the same is done at "arm's length"?*

Yes

Whether special resolution is passed/proposed?

Date of Special Resolution

Industry to which the entity being acquired belongs*

Precision Contract Research and Development Organization (CRO/ CDMO)

Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)*

The proposed investment in Galenvs will bring synergy to the business of the Company and Galenvs to develop new markets for its products. While Galenvs will be engaged in Discovery, Lead Optimization and Pre-clinical process development from 1 µmol to 10 mmol, and will transfer the technology to the Company for Phase I/ II/ III of clinical trials and for commercialization for scale up. The Company will gain for R&D pipeline arm for oligonucleotides, depth on a line already exists, process IP and know-how and a North American business growth opportunity.

Whether any governmental or regulatory approvals required for the acquisition?*

Provide brief details of any governmental or regulatory approvals

Whether the transaction will be in tranches*

Indicative time period for completion of the acquisition*

The Proposed Transaction is expected to be completed during the current financial year, subject to the completion of customary closing conditions and agreements

Nature of consideration- whether cash consideration or share swap or any other form and details of the same*

Cash

Share exchange ratio

Amount of cash consideration(Rs. in Crore)

0.38

Details of consideration

The Proposed Transaction is contemplated by way of: a. primary subscription to 8,092,857 common shares of the Galenvs at a consideration of USD 2.75 million, equivalent to 44% of the post-issue paid-up equity capital of Galenvs on diluted basis; and b. secondary acquisition from Founder shareholder of 2,942,857 common shares of Galenvs at a consideration of USD 1.00 million, equivalent to 16% of the post-issue paid-up equity capital of Galenvs on diluted basis.

Cost of acquisition or the price at which the shares are acquired (Total value) (Rs. in Crore)*

0.38

Existing percentage of shareholding held by acquirer*

0.00%

Percentage of Control acquired

Percentage of shares acquired (additional, if existing holding persists)

Brief background about the entity acquired in terms of products/line of business acquired*

Galenvs is a Montréal (Canada) based precision contract research and development organization (CRO/ CDMO) specializing in custom oligonucleotide synthesis and functional magnetic-nanoparticle (MNP) technologies for the diagnostics and therapeutics markets. The Company operates a vertically integrated platform spanning discovery, optimization, synthesis, purification, validation and pilot-scale production. Galenvs operates R&D and laboratory facilities in Montréal supporting oligonucleotide synthesis, purification, analytical testing, magnetic nanoparticle development and related process development activities.

Date of incorporation

26-09-2016

History of last 3 years turnover	Year Description (YYYY-YYYY)	Amount of turnover (Rs. in Crore)
1st Previous year turnover
2nd Previous year turnover
3rd Previous year turnover

Country in which the acquired entity has presence*

Galenvs has business operations in Montréal, Canada and it has presence in North America.

Any other significant information (in brief)